{"product_id":"orasure-bcg-matrix","title":"OraSure Technologies Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eOraSure’s BCG Matrix preview hints at which diagnostic products are pulling weight and which need a rethink—some look like Stars, others lean toward Cash Cows or Question Marks. Want the full picture with quadrant-by-quadrant reasoning, revenue and market-share data, and clear strategic moves? Purchase the complete BCG Matrix for a ready-to-use Word report plus an Excel summary that lets you present, decide, and act fast. Get instant access and stop guessing where to allocate your next dollar.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOraQuick HIV self-test (global)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraQuick HIV self-test remains a Star in 2024, holding leading procurement positions across LMIC programs due to WHO prequalification and strong brand recognition in global tenders. It commands a high share of the expanding HIV self-testing channel while burning cash on scale-up, distribution, and demand-generation. The runway to a cash cow is tangible if investment continues in access, awareness, and logistics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSaliva DNA collection (Oragene) for genomics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSaliva DNA collection (Oragene) sits in Stars: market-leading with research programs and select DTC players, supported by precision medicine budgets and cohort growth (All of Us \u0026gt;541,000 participants by 2024). The category is competitive yet OraSure kits remain default in many large studies while DTC channels have sold \u0026gt;30 million kits cumulatively. Growth is brisk, requiring working capital and promotional spend; double down on enterprise deals and clinical-grade validations to solidify share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMicrobiome collection (OMNIgene)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMicrobiome collection (OMNIgene) sits in Stars: translational trials and biobanking are scaling fast, with the microbiome market estimated by multiple industry reports to grow at high-teens CAGR through the late 2020s. OraSure leverages a recognized kit portfolio and sticky workflows from the DNA Genotek OMNIgene line, supporting widespread trial use and sample stability. High growth requires significant burn on studies, KOL engagement, and regulatory pathways, but preserving land‑standard status as the space matures makes continued investment strategically justified.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOral-fluid drug testing for workplace screening\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegulatory momentum and rising employer adoption are pushing oral-fluid workplace screening into a higher-growth segment; OraSure’s two decades of Intercept oral-fluid expertise supports superior usability and chain-of-custody compared with many point-of-collection alternatives.\u003c\/p\u003e\n\u003cp\u003eGrowth in oral-fluid testing is outpacing some lab-based urine panels, enabling share gains for OraSure if it leverages compliance credentials and expands national-account penetration.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory tailwinds: adoption rising\u003c\/li\u003e\n\u003cli\u003eCompetitive edge: oral-fluid chain-of-custody\u003c\/li\u003e\n\u003cli\u003eMarket dynamics: faster growth vs some lab methods\u003c\/li\u003e\n\u003cli\u003eStrategic focus: push compliance credentials + national accounts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHIV professional POC programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHIV professional POC programs remain Stars for OraSure in 2024 as community clinics and outreach expand rapid screening and demand for same‑visit results grows. OraSure’s training networks and established OraQuick footprint drive consistent testing volume and market access where speed‑to‑result is decisive. Continued funding for field support and partnerships is critical to secure tenders and sustain growth.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 focus: expand clinic\/outreach screening\u003c\/li\u003e\n\u003cli\u003eStrength: OraQuick footprint + training networks\u003c\/li\u003e\n\u003cli\u003eValue prop: leader in rapid speed-to-result\u003c\/li\u003e\n\u003cli\u003eAction: fund field support \u0026amp; partnerships to lock tenders\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStar portfolio: HIV lead, DTC kits \u003cstrong\u003e30M+\u003c\/strong\u003e; microbiome high‑teens CAGR\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOraQuick remains a Star in 2024, leading LMIC procurement and the HIV self-test channel while needing spend to scale to cash‑cow. Oragene\/DTC kits \u0026gt;30 million cumulative sales and All of Us \u0026gt;541,000 participants by 2024 keep Oragene a Star. OMNIgene rides a microbiome market growing at high‑teens CAGR, justifying continued investment to hold land‑standard status.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 signal\u003c\/th\u003e\n\u003cth\u003eKey metrics\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOraQuick\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003ctd\u003eLMIC procurement lead\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOragene\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;30M DTC kits; All of Us \u0026gt;541k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOMNIgene\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003ctd\u003eMicrobiome high‑teens CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eIn-depth BCG analysis of OraSure's portfolio, identifying Stars, Cash Cows, Question Marks and Dogs with clear investment guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG matrix for OraSure clarifies portfolio pain points for fast C-level decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHepatitis C rapid antibody test\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHepatitis C rapid antibody test delivers steady cash flow from mature demand, with public health screening programs in 2024 still targeting millions annually (US burden ~2.4 million chronic infections; global chronic infections ~58 million). High gross margins after distribution scale and modest promotional spend make it a reliable profit center that funds pipeline R\u0026amp;D. Prioritize manufacturing efficiency and defend pricing to preserve cash generation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished DTC ancestry\/research saliva kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy 2024 the DTC ancestry boom cooled to low single-digit annual growth, but volumes remain stable and predictable, supporting recurring demand. OraSure remains a preferred supplier with validated workflows and regulatory-compliant assays, enabling consistent unit economics. Cash cow characteristics: low growth, solid margin, minimal upkeep. Continue to milk with light innovation and supply-chain tune-ups to preserve profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntercept oral-fluid drug test (legacy accounts)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIntercept oral-fluid drug test legacy accounts remain entrenched in employer and government contracts and delivered steady cash flow, reporting roughly $35 million in revenue in fiscal 2024 per company disclosures, reflecting low-double-digit percent contribution to OraSure’s topline.\u003c\/p\u003e\n\u003cp\u003eHigh switching costs, documented compliance history and enrollment in long-term programs make these accounts sticky, reducing churn and preserving margin.\u003c\/p\u003e\n\u003cp\u003eNot a growth driver, it pays the bills; focus on optimizing COGS and operations and avoid heavy promotional spend that would compress returns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecimen stabilization OEM lines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSpecimen stabilization OEM lines are white-label kit components that ride customers’ installed bases, enabling incremental throughput lifts via upgrades without heavy marketing. They generate steady cash with limited field support, lowering cost-to-serve while protecting SLAs and expanding basket size through add-on consumables and service agreements.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWhite-label kits leverage installed base\u003c\/li\u003e\n\u003cli\u003eUpgrades raise throughput, minimal marketing\u003c\/li\u003e\n\u003cli\u003eHigh cash conversion, limited field support\u003c\/li\u003e\n\u003cli\u003eProtect SLAs and expand basket size\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlcohol screening products (e.g., Q.E.D.)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAlcohol screening products such as Q.E.D. sit squarely in Cash Cows: steady occupational and law‑enforcement demand underpins predictable reorder cycles. The category is mature with minimal growth, delivering recurring cash flows with limited incremental capex. Maintain lean operations and protect distribution reach to sustain margin contribution.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSteady occupational and law‑enforcement demand\u003c\/li\u003e\n\u003cli\u003eMature category, minimal growth\u003c\/li\u003e\n\u003cli\u003eRecurring cash with limited capex\u003c\/li\u003e\n\u003cli\u003eKeep lean; preserve distribution reach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCash cows fund R\u0026amp;D: protect margins with tight COGS, SLAs and minimal promotion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCash cows (Hep C rapid test; DTC ancestry stable; Intercept drug test ~$35M 2024; Q.E.D. alcohol screens; specimen stabilization OEM) generate steady, low-growth high-margin cash supporting R\u0026amp;D; focus on COGS, SLAs, minimal promo.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 Rev\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHep C rapid test\u003c\/td\u003e\n\u003ctd\u003esteady (public screening)\u003c\/td\u003e\n\u003ctd\u003emature\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTC ancestry\u003c\/td\u003e\n\u003ctd\u003elow-single-digit growth volumes\u003c\/td\u003e\n\u003ctd\u003estable\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntercept drug test\u003c\/td\u003e\n\u003ctd\u003e$35M\u003c\/td\u003e\n\u003ctd\u003estable\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eOraSure Technologies BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the exact BCG Matrix report you'll receive after purchase. No watermarks, no demo content—just a fully formatted, analysis-ready document designed for strategic clarity. It’s crafted with market-backed insight and delivered straight to your inbox. Once bought, it’s immediately editable, printable, and presentation-ready for your team or clients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55674535543161,"sku":"orasure-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/orasure-bcg-matrix.png?v=1755791179","url":"https:\/\/portersfiveforce.com\/products\/orasure-bcg-matrix","provider":"Porter's Five Forces","version":"1.0","type":"link"}